J. Scott Garland - 16 Oct 2023 Form 4 Insider Report for Olema Pharmaceuticals, Inc. (OLMA)

Role
Director
Signature
/s/ Shane Kovacs, Attorney-in-Fact
Issuer symbol
OLMA
Transactions as of
16 Oct 2023
Net transactions value
$0
Form type
4
Filing time
17 Oct 2023, 16:43:52 UTC
Previous filing
26 Jun 2023
Next filing
28 May 2024
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction OLMA Stock Option (Right to Buy) Award $0 +21,520 $0.000000 21,520 16 Oct 2023 Common Stock 21,520 $10.54 Direct F1
transaction OLMA Stock Option (Right to Buy) Award $0 +14,347 $0.000000 14,347 16 Oct 2023 Common Stock 14,347 $10.54 Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The shares subject to the option vest in a series of 36 successive equal monthly installments measured from October 16, 2023, subject to the Reporting Person's continuous service through each applicable vesting date.
F2 The shares subject to the option vest in equal monthly installments measured from October 16, 2023, subject to the Reporting Person's continuous service through each applicable vesting date. Such shares will vest in full on the earlier of June 16, 2024 and the date of the Issuer's next annual meeting of stockholders, subject to the Reporting Person's continuous service through such vesting date.